Sanofi, Regeneron Lose U.S. Patent Challenge to Amgen Cholesterol Drug Sanofi, Regeneron Lose U.S. Patent Challenge to Amgen Cholesterol Drug

Biotech company Amgen Inc said on Monday a U.S. jury confirmed the validity of patents on its cholesterol drug Repatha (evolocumab), rejecting a challenge by Regeneron Pharmaceuticals Inc and Sanofi SA.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news